Used in targeted cancer therapy, particularly for tumors overexpressing EGFR such as non-small cell lung cancer, colorectal cancer, and head and neck squamous cell carcinomas. Binds specifically to the extracellular domain of EGFR, blocking ligand binding and downstream signaling pathways involved in cell proliferation, survival, and metastasis. Serves as a reference standard in immunoassays and diagnostic development to evaluate EGFR expression levels and monitor therapeutic efficacy. Also utilized in research settings to study EGFR biology and validate new anti-EGFR agents.